These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9761357)

  • 1. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
    Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
    Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
    Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
    Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
    Ferrari S; Pieretti F; Verri E; Tolentinis L; Cesari M; Versari M; Zolezzi C; Lamanna G; Bacci G
    Anticancer Drugs; 2005 Aug; 16(7):733-8. PubMed ID: 16027521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
    Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
    J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
    Longhi A; Macchiagodena M; Vitali G; Bacci G
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):292-6. PubMed ID: 12679642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
    Hartmann JT; Knop S; Fels LM; van Vangerow A; Stolte H; Kanz L; Bokemeyer C
    Anticancer Drugs; 2000 Jan; 11(1):1-6. PubMed ID: 10757556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
    Fox E; Levin K; Zhu Y; Segers B; Balamuth N; Womer R; Bagatell R; Balis F
    Oncologist; 2018 Jul; 23(7):762-e79. PubMed ID: 29445029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of large osteosarcoma in children: new approach.
    Kobys VL; Konovalenko VF; Repinа NV; Golovko TS; Gulak LO; Tarasova TO; Zaharycheva EV; Matyushok OF
    Exp Oncol; 2013 Jun; 35(2):105-8. PubMed ID: 23828385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
    Janeway KA; Grier HE
    Lancet Oncol; 2010 Jul; 11(7):670-8. PubMed ID: 20347613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
    Rosen G
    Cancer Treat Res; 1993; 62():49-54. PubMed ID: 8096759
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
    J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
    Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
    J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
    Ferrari S; Bielack SS; Smeland S; Longhi A; Egerer G; Sundby Hall K; Donati D; Kevric M; Brosjö O; Comandone A; Werner M; Monge O; Palmerini E; Berdel WE; Bjerkehagen B; Paioli A; Lorenzen S; Eriksson M; Gambarotti M; Tunn PU; Jebsen NL; Cesari M; von Kalle T; Ferraresi V; Schwarz R; Bertulli R; Kasparek AK; Grignani G; Krasniqi F; Sorg B; Hecker-Nolting S; Picci P; Reichardt P
    Tumori; 2018; 104(1):30-36. PubMed ID: 29218692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.